#United States #Rosemont #dermatology #Hidradenitis Suppurativa #Medical Guidelines

New Guidelines for Managing Hidradenitis Suppurativa

Recently, the American Academy of Dermatology (AAD) and the Hidradenitis Suppurativa Foundation (HSF) have unveiled the first-ever joint guidelines for the management of hidradenitis suppurativa (HS), a chronic skin condition affecting more than three million people in the United States. This collaborative effort aims to enhance patient care and provide a structured approach to HS management.

Understanding Hidradenitis Suppurativa

Hidradenitis suppurativa is characterized by painful lumps and inflammation, typically located in areas where skin rubs together such as the armpits, groin, and inner thighs. Due to its complex nature, HS is often misdiagnosed as acne or infections, leading to delays in appropriate treatment. An accurate diagnosis by a board-certified dermatologist is crucial for successful management of the condition.

Dr. Murad Alam, AAD President, emphasizes the significance of early diagnosis and comprehensive care, stating, "Dermatologists not only diagnose HS but also screen for associated medical and psychiatric conditions, enabling a more holistic approach to patient care."

Evidence-Based Recommendations

The newly published guidelines, found in the Journal of the American Academy of Dermatology (JAAD), comprise 37 evidence-based recommendations tailored to treat chronic HS and manage acute flares. These guidelines set a quality standard for HS care, ensuring all patients have access to suitable treatment strategies.

In the realm of strong recommendations, biologics such as adalimumab and infliximab are highly endorsed for patients with moderate-to-severe HS. These medications have demonstrated efficacy in significantly reducing the occurrence of abscesses and nodules. Abscesses, which are painful pockets of pus beneath the skin, can severely disrupt the quality of life for those affected.

Conditional Recommendations for Comprehensive Care

In addition to strong endorsements, conditional recommendations have been outlined, offering more flexibility based on individual patient circumstances. Treatments considered include:

• - Topical Therapies: Using clindamycin and ruxolitinib to mitigate symptoms.
• - Systemic Antibiotics: Medications like doxycycline are suggested for overall symptom management.
• - Hormonal Therapy: Spironolactone can be administered to lessen condition severity.
• - In-office Procedures: Dermatologists may opt for interventions such as incision and drainage or laser treatments for recurring abscesses.

Dr. Haley B. Naik, co-chair of the guideline work group, emphasizes the need for a shared understanding among dermatologists, patients, and insurers: "These guidelines create a roadmap for high-quality HS care, ensuring that all individuals with HS receive treatment that aligns with current evidence."

Barriers to Effective Treatment

One significant challenge facing HS patients is step therapy, a practice requiring patients to try less effective treatments before approval for preferred medications. Evidence indicates that step therapy is often inappropriate in HS management, delaying essential care. Advocating against this barrier is vital to improving patient outcomes.

Supportive and Complementary Care

While the recent guidelines focus on primary treatment options, supportive management is also crucial. Patients experiencing sudden or chronic pain may benefit from pain relief strategies, including nonsteroidal anti-inflammatory drugs or local anesthetics. Lifestyle changes, including cessation of tobacco and maintaining a heart-healthy diet, are also encouraged to enhance overall well-being.

The Importance of Medical Oversight

As the guidelines recommend various treatment options, the importance of customizing care for each patient remains paramount. Patients are encouraged to consult with a board-certified dermatologist for individualized assessment and care plans that address their specific needs.

In summary, the AAD and HSF have made substantial strides towards improving the quality of care for those battling hidradenitis suppurativa. With these newly established guidelines, patients are one step closer to obtaining the informed, comprehensive care they deserve to lead fulfilling lives despite the challenges posed by HS. For more information on finding a qualified dermatologist, visit aad.org/findaderm.